Production of recombinant HIV-1 Nef protein using different expression host systems: A techno-economical comparison

Biotechnology Progress

Volumn 25, Issue 1, 2009, Pages 95-102

  Vermasvuori, Raisa ^a   Koskinen, Jani ^b   Salonen, Katri ^b   Sirén, Noora ^a   Weegar, Jan ^c   Dahlbacka, John ^c   Kalkkinen, Nisse ^d   Von Weymarn, Niklas ^a  

^a AALTO UNIVERSITY   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c ÅBO AKADEMI UNIVERSITY   (Finland)

^d UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Bioreactor; Costs; Economical evaluation; Hiv 1 negative factor (Hiv 1 nef); Recombinant protein production; Recombinant protein purification; Techno economical comparison

Indexed keywords

ECONOMICAL EVALUATION; HIV-1 NEGATIVE FACTOR (HIV-1 NEF); RECOMBINANT PROTEIN PRODUCTION; RECOMBINANT PROTEIN PURIFICATION; TECHNO-ECONOMICAL COMPARISON;

BIOCONVERSION; BIOREACTORS; CELL CULTURE; COST ACCOUNTING; EMPLOYMENT; ESCHERICHIA COLI; INDUSTRIAL CHEMICALS; PROTEINS; PURIFICATION; WAGES;

COSTS;

ESCHERICHIA COLI; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; PICHIA PASTORIS;

NEF PROTEIN; NEF PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; RECOMBINANT PROTEIN;

ANIMAL; ARTICLE; CELL LINE; DROSOPHILA; ECONOMICS; ESCHERICHIA COLI; GENETICS; METABOLISM; METHODOLOGY; PICHIA; PROTEIN ENGINEERING;

ANIMALS; CELL LINE; DROSOPHILA; ESCHERICHIA COLI; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; PICHIA; PROTEIN ENGINEERING; RECOMBINANT PROTEINS;

EID: 64549090311     PISSN: 87567938     EISSN: None     Source Type: Journal    
DOI: 10.1002/btpr.69     Document Type: Article

References (37)

1. J. Koskinen: FIT Biotechnology Oyj Plc., Biokatu 8, FI-33520 Tampere, Finland.
2. K. Salonen: Ipsat Therapies Ltd, Viikinkaari 4, FI-00790 Helsinki, Finland.
3. N. von Weymarn: VTT Technical Research Centre of Finland, P.O. Box 1000, FI-02044 VTT, Finland.
4. Lawrence S. Biotech drug market steadily expands. Nat Biotechnol. 2005;23:1466-1466.
5. Pavlou AK, Reichert JM. Recombinant protein therapeutics: success rates, market trends and values to 2010. Nat Biotechnol. 2004;22:1513-1519.
6. Berry S. Biotech meets the investors. Trends Biotechnol. 2002; 20:370-371.
7. Walsh G. Biopharmaceutical benchmarks 2006. Nat Biotechnol.2006;24:769-776.
8. Squires CH, Retallack DM, Chew LC, Ramseier TM, Schneider JC, Talbot HW. Heterologous protein production in P. fluorescens. BioProcess Int. 2004;2:36-14.
9. Ikonomou L, Schneider YJ, Agathos SN. Insect cell culture for industrial production of recombinant proteins. Appl Microbiol Biotechnol. 2003;62:1-20.
10. Walsh G. Biopharmaceutical benchmarks 2003. Nat. Biotechnol. 2003;21:865-870.
11. Anonymous GlaxoSmithKline.http://www.gsk.com/. 2008.
12. Baxter SC, Panarello D, Ajith S, Bhattacharya M, Chaiken IM. Recombinant-protein production in insect cells utilizing a hollow-fibre bioreactor. Biotechnol Appl Biochem. 2006;45:167-172.
13. Yin J, Li G, Ren X, Herrler G. Select what you need: a compar-ative evaluation of the advantages and limitations of frequently used expression systems for foreign genes. J Biotechnol. 2007; 127:335-347.
14. Arold ST, Baur AS. Dynamic Nef and Nef dynamics: how structure could explain the complex activities of this small HIV protein. Trends Biochem Sci. 2001;26:356-363.
15. Deacon NJ, Tsykin A, Solomon A, Smith K, Ludford-Menting M, Hooker DJ, McPhee DA, Greenway AL, Ellett A, Chatfield C, Lawson VA, Crowe S, Maerz A, Sonza S, Learmont J, Sulli-van JS, Cunningham A, Dwyer D, Dowton D, Mills J. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science. 1995;270:988-991.
16. Geyer M, Peterlin BM. Domain assembly, surface accessibility and sequence conservation in full length HIV-1 Nef. FEBS Lett. 2001;496:91-95.
17. Kaminchik J, Bashan N, Pinchasi D, Amit B, Sarver N, John-ston MI, Fischer M, Yavin Z, Gorecki M, Panet A. Expression and biochemical characterization of human immunodeficiency virus type 1 nef gene product. J Virol. 1990;64:3447-3454.
18. Kohleisen B, Gaedigk-Nitschko K, Ohlmann M, Goetz E, Osto- laza H, Goni FM, Erfle V. Heparin-binding capacity of the HIV-1 NEF-protein allows one-step purification and biochemi-cal characterization. J Virol Methods. 1996;60:89-101.
19. Arold S, Franken P, Strub MP, Hoh F, Benichou S, Benarous R, Dumas C. The crystal structure of HIV-1 Nef protein bound to the Fyn kinase SH3 domain suggests a role for this complex in altered T cell receptor signaling. Structure. 1997;5:1361-1372.
20. Azad AA, Failla P, Lucantoni A, Bentley J, Mardon C, Wolfe A, Fuller K, Hewish D, Sengupta S, Sankovich S, Grgacic E, McPhee D, Macreadie I. Large-scale production and characteri-zation of recombinant human immunodeficiency virus type 1 Nef. J Gen Virol. 1994;75:651-655.
21. Franken P, Arold S, Padilla A, Bodeus M, Hoh F, Strub MP,Boyer M, Jullien M, Benarous R, Dumas C. HIV-1 Nef protein: purification, crystallizations, and preliminary X-ray diffraction studies. Protein Sci. 1997;6:2681-2683.
22. Finzi A, Cloutier J, Cohen EA. Two-step purification of His- tagged Nef protein in native condition using heparin and immo-bilized metal ion affinity chromatographies. J Virol Methods. 2003;111:69-73.
23. James CO, Huang M, Khan M, Garcia-Barrio M, Powell MD, Bond VC. Extracellular Nef protein targets CD4 T cells for apoptosis by interacting with CXCR4 surface receptors. J Virol. 2004;78:3099-3109.
24. Macreadie IG, Ward AC, Failla P, Grgacic E, McPhee D, Azad AA. Expression of HIV-1 nef in yeast: the 27 kDa Nef protein is myristylated and fractionates with the nucleus. Yeast. 1993;9:565-573.
25. Collings A, Pitka"nen J, Strengell M, Ta"htinen M, Lagerstedt A, Hakkarainen K, Ovod V, Sutter G, Ustav M, Ustav E, Ma"nnik A, Ranki A, Peterson P, Krohn K. Humoral and cellular immune responses to HIV-1 nef in mice DNA-immunised with non-replicating or self-replicating expression vectors. Vaccine. 1999;18:460-467.
26. Ta"htinen M, Strengell M, Collings A, Pitkanen J, Kjerrstro"mA, Hakkarainen K, Peterson P, Kohleisen B, Wahren B, Ranki A, Ustav M, Krohn K. DNA vaccination in mice using HIV-1 nef, rev and tat genes in self-replicating pBN-vector. Vaccine. 2001;19:2039-2047.
27. Janvier K, Craig H, Le Gall S, Benarous R, Guatelli J, Schwartz O, Benichou S. Nef-induced CD4 downregulation: a diacidic sequence in human immunodeficiency virus type 1 Nef does not function as a protein sorting motif through direct binding to beta-COP. J Virol. 2001;75:3971-3976.
28. Liang X, Fu T, Xie H, Emini EA, Shiver JW. Development of HIV-1 Nef vaccine components: immunogenicity study of Nef mutants lacking myristoylation and dileucine motif in mice. Vaccine. 2002;20:3413-3421.
29. Muratori C, Schiavoni I, Melucci-Vigo G, Olivetta E, Santar- cangelo AC, Pugliese K, Verani P, Federico M. Inducible expression of the delta NGFr/F12Nef fusion protein as a new tool for anti-human immunodeficiency virus type 1 gene ther-apy. Hum Gene Ther. 2002;13:1751-1766.
30. Blazevic V, Mannik A, Malm M, Sikut R, Valtavaara M, Toots U, Ustav M, Krohn K. Induction of human immunodeficiency virus type-1-specific immunity with a novel gene transport unit (GTU)-MultiHIV DNA vaccine. AIDS Res Hum Retroviruses.2006;22:667-677.
31. Krohn K, Stanescu I, Blazevic V, Vesikari T, Ranki A, Ustav M. A DNA HIV-1 vaccine based on a fusion gene expressing non- structural and structural genes of consensus sequence of the A-C subtypes and the ancestor sequence of the F-H subtypes. Preclini- cal and clinical studies. Microbes Infect. 2005;7:1405-1413.
32. Lin H. Cellular responses to the induction of recombinant genes in Escherichia coli fed-batch cultures, Academic dissertation, Martin-Luther-Universitat Halle-Wittenberg, Germany, 2000.
33. Holme T, Arvidson S, Lindholm B, Pavlu B. Enzymes: Laboratory-scale production. Process Biochem. 1970;5:62-66.
34. Korz DJ, Rinas U, Hellmuth K, Sanders EA, Deckwer W. Simple fed-batch technique for high cell density cultivation of Esch- erichia coli. J Biotechnol. 1995;39:59-65.
35. Jahic M, Wallberg F, Bollok M, Garcia P, Enfors SO. Temp-erature limited fed-batch technique for control of proteolysis in Pichia pastoris bioreactor cultures. Microb Cell Fact. 2003;2:6.
36. Siren N, Weegar J, Dahlbacka J, Kalkkinen N, Fagervik K, Leisola M, von Weymarn N. Production of recombinant HIV-1 Nef (negative factor) protein using Pichia pastoris and a low-tem-perature fed-batch strategy. Biotechnol Appl Biochem. 2006;44: 151-158.
37. Resh MD. Fatty acylation of proteins: new insights into membrane targeting of myristoylated and palmitoylated proteins. Biochim Biophys Acta. 1999;1451:1-16.